دورية أكاديمية
أعرض في EDS

Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
المؤلفون: Wang JS; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Wong T; Department of Radiology, Division of Nuclear Medicine and Radiotheranostics, Duke University, Durham, North Carolina, USA., Wu KA; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Mullikin TC; Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA., Armstrong A; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA andrew.armstrong@duke.edu.; Duke Cancer Institute, Durham, North Carolina, USA.; Center for Prostate & Urologic Cancers, Duke Cancer Institute, Durham, North Carolina, USA.
المصدر: BMJ case reports [BMJ Case Rep] 2024 Feb 23; Vol. 17 (2). Date of Electronic Publication: 2024 Feb 23.
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101526291 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-790X (Electronic) Linking ISSN: 1757790X NLM ISO Abbreviation: BMJ Case Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BMJ Pub. Group
مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/radiotherapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Pneumonia*/drug therapy , Dipeptides* , Heterocyclic Compounds, 1-Ring* , Radioisotopes*, Male ; Humans ; Lutetium/adverse effects ; Treatment Outcome ; Prostate-Specific Antigen ; Radiopharmaceuticals/adverse effects
مستخلص: We present the case of a patient with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) who received lutetium Lu-177 vipivotide tetraxetan (also known as 177 Lu-PSMA-617) due to progressive disease despite chemotherapy, hormonal therapy and radiation, including palliative mediastinal and central nervous system radiation. He was subsequently hospitalised for worsening acute onset dyspnoea despite clinically responding to therapy. Interval imaging revealed progressive multifocal ground-glass opacities superimposed on a background of underlying peribronchovascular fibrosis. Further workup, including an extensive workup to identify a possible infectious aetiology, ruled out most aetiologies leaving radiation pneumonitis (RP), radiation recall pneumonitis (RRP) and drug-induced pneumonitis as possible diagnoses secondary to 177 Lu -PSMA-617. The associated imaging findings of ground-glass opacities and consolidation can be like other aetiologies such as acute infection and subsequently may be treated incorrectly. In the use of theragnostics like 177 Lu -PSMA-617, it is fundamental to apply the practices of radioprotection learnt from radiotherapy, as well as to consider prior radiotherapy treatments and their possible side effects when used in conjunction.
Competing Interests: Competing interests: Andrew Armstrong receives consulting income (personal) and grant funding (to Duke University) from Novartis.
(© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-17. (PMID: 35609224)
Future Sci OA. 2019 Apr 10;5(5):FSO378. (PMID: 31245041)
Radiat Oncol J. 2017 Jun;35(2):163-171. (PMID: 28712275)
Thyroid. 2010 Mar;20(3):337-40. (PMID: 20187786)
Lancet Respir Med. 2019 Apr;7(4):347-357. (PMID: 30876831)
Radiographics. 2019 Nov-Dec;39(7):1923-1937. (PMID: 31584861)
Cancer Res. 1981 Jun;41(6):2338-42. (PMID: 7237432)
Cancer Biol Med. 2012 Sep;9(3):202-4. (PMID: 23691480)
J Clin Oncol. 2021 Apr 20;39(12):1371-1382. (PMID: 33617303)
J Immunother Cancer. 2020 Jun;8(1):. (PMID: 32581061)
Lancet. 2020 Apr 11;395(10231):1208-1216. (PMID: 32209449)
JCO Precis Oncol. 2017 May 26;1:. (PMID: 32913972)
N Engl J Med. 2017 Nov 16;377(20):1919-1929. (PMID: 28885881)
BMC Pulm Med. 2021 Jan 6;21(1):9. (PMID: 33407290)
Front Oncol. 2023 Jan 16;13:977160. (PMID: 36726383)
J Nucl Med. 2006 Dec;47(12):1977-84. (PMID: 17138740)
Eur J Pharm Biopharm. 2020 Nov;156:191-202. (PMID: 32941997)
N Engl J Med. 2021 Sep 16;385(12):1091-1103. (PMID: 34161051)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
J Clin Oncol. 2017 Jan;35(1):56-62. (PMID: 28034064)
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2188-2195. (PMID: 36826478)
فهرسة مساهمة: Keywords: drug interactions; prostate cancer; radiotherapy; safety
المشرفين على المادة: BRH40Y9V1Q (Lutetium-177)
0 (PSMA-617)
5H0DOZ21UJ (Lutetium)
EC 3.4.21.77 (Prostate-Specific Antigen)
0 (Radiopharmaceuticals)
0 (Dipeptides)
0 (Heterocyclic Compounds, 1-Ring)
0 (Radioisotopes)
تواريخ الأحداث: Date Created: 20240223 Date Completed: 20240226 Latest Revision: 20240521
رمز التحديث: 20240521
مُعرف محوري في PubMed: PMC10895240
DOI: 10.1136/bcr-2023-257772
PMID: 38395466
قاعدة البيانات: MEDLINE
الوصف
تدمد:1757-790X
DOI:10.1136/bcr-2023-257772